Ledipasvir/sofosbuvir (trade name Harvoni) is a two-drug combination for the treatment of hepatitis C.
Ledipasvir
Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.
Deleobuvir
Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C.
Ombitasvir
Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection.
Velpatasvir
Velpatasvir is an inhibitor of NS5A used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.
Velpatasvir/sofosbuvir
Velpatasvir/sofosbuvir (trade name Epclusa) is a two-drug combination for the treatment of hepatitis C.
Daclatasvir
Daclatasvir (trade name Daklinza) is a drug for the treatment of hepatitis C (HCV).
Ravidasvir
Ravidasvir (PPI-668) is an investigational NS5A inhibitor in clinical trials for chronic hepatitis C genotype 4.
Odalasvir
Odalasvir (INN, previously known as ACH-3102) is an investigational new drug in development for the treatment of hepatitis C.
Sofosbuvir/daclatasvir
Daclatasvir/sofosbuvir (trade name Darvoni) is a two-drug combination for the treatment of hepatitis C.
Samatasvir
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C.
Studylib tips
Did you forget to review your flashcards?
Try the Chrome extension that turns your New Tab screen into a flashcards viewer!
The idea behind Studylib Extension is that reviewing flashcards will be easier if we distribute all flashcards reviewing into smaller sessions throughout the working day.